
Janssen says Imbruvica shows improved PFS in blood cancer in long-term effectiveness study
pharmafile | June 14, 2016 | News story | Manufacturing and Production, Research and Development | Janssen, blood cancer, drug trial, imbruvica
Janssen said late-stage studies to test long-term effectiveness for its Imbruvica (ibrutinib) in blood cancer showed improved progression free survival of 74.8%.
The company said the drug to treat Chronic Lymphocytic Leukaemia (CLL) and mantle cell lymphoma (MCL) also demonstrated a higher overall response rate.
Rozlyn Bekker, medical director of Janssen, said: “The data not only helps improve our understanding of ibrutinib patient populations, but also firmly strengthen the evidence base for the efficacy of the treatment in CLL and MCL.”
Imbruvica is a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, which works by forming a strong covalent bond with BTK to block the transmission of cell survival signals within the malignant B cells. By blocking this BTK protein, ibrutinib helps kill and reduce the number of cancer cells. It also slows down the worsening of the cancer.
Ibrutinib is currently approved in Europe for the treatment of adult patients with relapsed or refractory MCL, and previously untreated adult patients with CLL.
Anjali Shukla
Related Content

ViroCell Biologics and AvenCell Therapeutics partner to accelerate allogeneic CAR-T therapy development
ViroCell Biologics has announced a new manufacturing collaboration with AvenCell Therapeutics to produce a high-yield …

Sarclisa recommended for EU approval in newly diagnosed multiple myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s …

New CAR T Vision Coalition and roadmap report to launch at ASCO aims to double patients treated with CAR T-cell therapy by 2030
For people living with aggressive blood cancers, CAR T-cell therapy offers hope for a longer, …






